Skip to main content

Download

Audience for the document: Share Class: Language of the document:

Download

Share Class: Language of the document:

Change Details

If you need to change your email address please contact us.
Subscriptions
OK
You are ready to start subscribing.
Get started by going to our products or insights section to follow what you're interested in.

Products Insights

GIPS® Information

T. Rowe Price ("TRP") claims compliance with the Global Investment Performance Standards (GIPS®) and has prepared and presented this report in compliance with the GIPS standards. T. Rowe Price has been independently verified for the twenty four-year period ended June 30, 2020, by KPMG LLP. The verification report is available upon request. A firm that claims compliance with the GIPS standards must establish policies and procedures for complying with all the applicable requirements of the GIPS standards. Verification provides assurance on whether the firm’s policies and procedures related to composite and pooled fund maintenance, as well as the calculation, presentation, and distribution of performance, have been designed in compliance with the GIPS standards and have been implemented on a firm-wide basis. Verification does not provide assurance on the accuracy of any specific performance report.

TRP is a U.S. investment management firm with various investment advisers registered with the U.S. Securities and Exchange Commission, the U.K. Financial Conduct Authority, and other regulatory bodies in various countries and holds itself out as such to potential clients for GIPS purposes. TRP further defines itself under GIPS as a discretionary investment manager providing services primarily to institutional clients with regard to various mandates, which include U.S, international, and global strategies but excluding the services of the Private Asset Management group.

A complete list and description of all of the Firm's composites and/or a presentation that adheres to the GIPS® standards are available upon request. Additional information regarding the firm's policies and procedures for calculating and reporting performance results is available upon request

Other Literature

You have successfully subscribed.

Notify me by email when
regular data and commentary is available
exceptional commentary is available
new articles become available

Thank you for your continued interest

Please enter valid search characters

December 2020 / MARKET RESEARCH

Innovation Drives Health Care Sector’s Response to Pandemic

We may be on the cusp of a sea change in medicine.

Key Insights

  • The health care sector’s rapid response to the coronavirus pandemic highlights the accelerating pace of innovation in the space.
  • Gene sequencing and other scientific breakthroughs over the past 20 years could set the stage for a transformative decade in health care.
  • A rapidly expanding universe of investable companies and innovation‑driven disruption could favor stock pickers with deep scientific and industry knowledge.

Encouraging progress in the race to develop an effective vaccine for COVID‑19, the disease caused by the coronavirus, could bode well for efforts to stem the pandemic and support a broader recovery in the economy.

We believe the biopharma and health care services industries’ relatively rapid response in battling the coronavirus illustrates the innovation in the health care sector more broadly.

Amid this rapid change, we think that our investment team’s diverse scientific and medical backgrounds, coupled with our prudent investment approach, give us an edge in identifying companies that should benefit from this wave of innovation.

Pandemic Solutions: Darkest Before the Dawn

Tragically, the rising number of coronavirus infections and the approach of winter—usually the peak transmission period for respiratory ailments—suggest that the next two to three months could be the worst of the pandemic.

Despite this sobering near‑term outlook, recent developments on the vaccine and treatment fronts give us hope that we are closer to the beginning of the end of the pandemic. COVID‑19 is unlikely to be eliminated completely, but there are signs that the disease could become significantly more manageable.

Multiple Shots on Goal

A selection of coronavirus vaccine candidates.

A selection of coronavirus vaccine candidates.

As of October 31, 2020.

Sources: T. Rowe Price, Centers for Disease Control, and company reports.

See Additional Disclosures at the end for more information.

1 Estimated timing of key readouts from clinical trials, based on publicly available data. These estimates are subject to change.

Pfizer and Moderna had a pivotal data release in November 2020

Early data from trials of potential vaccines based on messenger ribonucleic acid (mRNA)—an intermediary that transmits information encoded in our DNA to proteins that carry out specified actions—have demonstrated high efficacy rates in preventing COVID‑19 infection. Fundamentally, these mRNA‑based vaccines aim to enable the body to produce its own protein therapeutic to fight the virus.

Questions remain about the duration of the immunity created by these fast‑tracked vaccine candidates. We’re also mindful that mutations in the virus could reduce the efficacy of the therapies currently in development.

Fortunately, the virus appears to have remained relatively stable thus far—unlike the flu, which mutates quickly. The global biopharma complex is also pursuing about a dozen different vaccine candidates, giving humanity multiple shots on goal, so to speak. Although infection rates are soaring, it appears that behavioral changes, such as physical distancing and increased wearing of face masks, as well as advances in the medical community’s understanding and treatment of COVID‑19, have helped to reduce the disease’s mortality rate.

Innovation, Accelerated

That the biopharma industry has leveraged a diverse slate of technologies and platforms to develop the many potential candidates for COVID‑19 vaccines and therapies—compressing into mere months a process that, in the past, could have taken a decade—is a testament to the scientific advances of the past 20 years.

This impressive feat potentially could engender a favorable regulatory climate for drug approvals, while the pandemic may also prompt governments and the industry to take a more proactive approach to investment in diagnostics, vaccines, and treatments for infectious diseases.

Beyond drug development, the virus accelerated the adoption of “telehealth” services and other types of virtual health care. Remote monitoring of patients with chronic diseases and the adoption of telemedicine as a replacement for some in‑person doctor visits, as well as the shift of less‑acute care from the hospital to the home and outpatient centers, generally have proved convenient, efficient, and economical.

On the Cusp of a Sea Change in Health Care

The health care sector, in our view, could be on the cusp of a transformative decade during which scientific and technologic breakthroughs of the past 20 years could begin to bear fruit in the form of new treatments that help address unmet clinical needs and improve patients’ quality of life.

This sea change could be akin to the evolution of the internet, a significant innovation that did not mean much to many people’s daily lives for some time but grew to be indispensable as widespread connectivity and low‑cost computing power enabled the development of today’s most popular applications.

Consider genetic sequencing, a capability that existed 20 years ago but has become much cheaper with advances in science and technology, reaching the point that we can sequence the genomes of mass populations—as deCODE famously did in Iceland—to unlock powerful insights. By analyzing these troves of genetic data and health records, we can identify mutations in people who did not develop Alzheimer’s disease (or other chronic ailments) and leverage these findings to develop better diagnostics, treatment plans, and potential therapeutics. So‑called liquid or fluid biopsies, for example, are blood tests that can detect certain cancers before the symptoms manifest themselves by identifying biomarkers associated with tumor development.

Biopharma’s toolkit has expanded beyond small molecules and targeted antibodies, with a wide range of areas showing potential promise, including therapies that engineer cells to kill cancer or gene‑editing technologies that seek to correct disease‑causing genetic mutations. Medicines based on mRNA turn the body into a bio‑factory to produce its own drugs, while precision tissue delivery can transport therapeutic payloads to highly targeted areas, potentially improving efficacy and minimizing harmful side effects. Protein degraders are another class of emerging treatments that eliminate specific disease‑causing proteins, potentially leading to therapies for ailments previously deemed “undruggable.”

In the coming years, advances in artificial intelligence and machine learning could also incrementally improve the success rate of new treatments by processing an array of factors to help identify the best chemical series to bring to trial.

Selectivity Is Key for Health Care Investors

This wave of innovation in health sciences, especially biopharma, has led to a proliferation of small companies leveraging emerging technologies and therapeutic methods, with an increasing number entering the public market at earlier stages in their development. This year, more than 70 biotechnology companies had completed their initial public offerings (IPO) through the end of October, an acceleration relative to 2019.

Ready access to capital is critical to driving innovation, but the ever‑expanding universe of public companies and accelerating disruption create challenges for investors. Among the roughly 435 biotech IPOs that took place from 2013 to the end of October, a mere 10 stocks accounted for more than 60% of the returns generated by this cohort.

We believe that this divergent performance favors active management and that our deep investment team, which includes experienced analysts with backgrounds in science and medicine, should give us an edge in identifying the names whose technologies, large addressable markets, and management teams give them a chance of growing to become much bigger companies.


Staying on Top of Innovation

Dr. Ziad Bakri explains how he and his team identify the small‑ and mid‑capitalization biotech companies that could have what it takes to grow much larger.

The bulk of the overall returns in the rapidly expanding universe of biotechnology stocks are driven by a relatively small portion of these companies. In the mid‑cap universe, we seek to identify the names where we have a degree of confidence that the repeatability of their platform gives them the potential to enter large‑cap territory. Among small‑cap biotech companies, we seek out developers of therapeutics in which the market may have not realized the company’s potential to build a much larger franchise.

Although the pandemic has limited our team’s travel and in‑person meetings, we stay in contact with senior executives and talk regularly with others in health care to find new investment ideas and validate our assumptions. Our investment team’s diverse scientific and medical backgrounds and deep contacts within industries and academia help them determine if a company’s story has potential or is overly promotional.

IMPORTANT INFORMATION

This material is being furnished for general informational purposes only. The material does not constitute or undertake to give advice of any nature, including fiduciary investment advice, and prospective investors are recommended to seek independent legal, financial and tax advice before making any investment decision. T. Rowe Price group of companies including T. Rowe Price Associates, Inc. and/or its affiliates receive revenue from T. Rowe Price investment products and services. Past performance is not a reliable indicator of future performance. The value of an investment and any income from it can go down as well as up. Investors may get back less than the amount invested.

The material does not constitute a distribution, an offer, an invitation, a personal or general recommendation or solicitation to sell or buy any securities in any jurisdiction or to conduct any particular investment activity. The material has not been reviewed by any regulatory authority in any jurisdiction.

Information and opinions presented have been obtained or derived from sources believed to be reliable and current; however, we cannot guarantee the sources' accuracy or completeness. There is no guarantee that any forecasts made will come to pass. The views contained herein are as of the date noted on the material and are subject to change without notice; these views may differ from those of other T. Rowe Price group companies and/or associates. Under no circumstances should the material, in whole or in part, be copied or redistributed without consent from T. Rowe Price.

The material is not intended for use by persons in jurisdictions which prohibit or restrict the distribution of the material and in certain countries the material is provided upon specific request.  

It is not intended for distribution to retail investors in any jurisdiction.

USA—Issued in the USA by T. Rowe Price Associates, Inc., 100 East Pratt Street, Baltimore, MD, 21202, which is regulated by the U.S. Securities and Exchange Commission. For Institutional Investors only.

© 2021 T. Rowe Price. All rights reserved. T. ROWE PRICE, INVEST WITH CONFIDENCE, and the bighorn sheep design are, collectively and/or apart, trademarks or registered trademarks of T. Rowe Price Group, Inc.

Previous Article

4 December 2020 / GLOBAL EQUITIES

Who Could Win in the Value vs. Growth Debate?
Next Article

7 December 2020 / JAPAN EQUITIES

For Investors in Japan, the Outlook Appears Suga Sweet
202011‑1425638

You are now leaving the T. Rowe Price website

T. Rowe Price is not responsible for the content of third party websites, including any performance data contained within them. Past performance cannot guarantee future results.